Akebia Therapeutics Unveils Key Research Findings at ASN Kidney Week
Akebia Therapeutics at ASN Kidney Week 2025
Akebia Therapeutics, Inc. (NASDAQ: AKBA), a dedicated biopharmaceutical organization specializing in kidney disease, proudly announces its participation in the American Society of Nephrology Kidney Week 2025. This major event is a hotspot for nephrology professionals and takes place in Houston, emphasizing the latest findings in kidney health.
Noteworthy Presentations by Akebia
During this esteemed gathering, notable presentations will highlight the latest clinical data related to vadadustat, Akebia's pioneering treatment for anemia stemming from chronic kidney disease (CKD). Dr. Glenn M. Chertow of Stanford University will lead the presentation of a critical win odds analysis related to mortality and hospitalization among patients enrolled in the INNO2VATE trials, a global Phase 3 clinical program aimed at assessing the efficacy of vadadustat.
Understanding Vadadustat
Vadadustat operates as a hypoxia-inducible factor prolyl hydroxylase inhibitor, influencing the body’s natural responses to low oxygen levels. This treatment notably stimulates the production of erythropoietin, crucial for hemoglobin and red blood cell production, thus managing anemia in CKD patients. Following its U.S. approval for use among adults on dialysis, Akebia continues to expand on its promising research.
Engagement with the Nephrology Community
Steven Burke, MD, Senior Vice President and Chief Research & Development Officer at Akebia, shared insights on their ongoing commitment: "Our engagement with the nephrology community plays a critical role in clarifying the treatment landscape. Achieving transparent data-sharing guarantees that healthcare professionals are equipped with essential knowledge to make informed therapeutic decisions."
Key Oral Presentation Details
Among the highlights of the ASN Kidney Week will be an oral presentation discussing:
Win-Odds Analysis of Deaths and Hospitalization in Patients Taking Vadadustat or Darbepoetin Alfa for CKD-related Anemia Undergoing Dialysis
Presenter: Glenn M. Chertow, MD
Session Date/Time: November 6, 2025; 4:30 PM to 6:00 PM
Session Room: Room 351D (Convention Center)
Poster Presentations at ASN Kidney Week
Additionally, Akebia will feature several poster presentations relevant to vadadustat:
Model-Based VAFSEO Starting Dose Recommendations in Dialysis-Dependent CKD Patients
Poster #: TH-PO902
November 6, 2025; 10:00 AM-12:00 PM CDT
Vadadustat Outcomes In-Center Experience (VOICE) Study: A Pragmatic Randomized Controlled Trial Testing Safety of Three Times Weekly Vadadustat
Poster #: FR-PO0204
November 7, 2025; 10:00 AM-12:00 PM CDT
Consistency of the Estimate of Responsiveness of Vadadustat vs. Darbepoetin
Poster #: FR-PO0202
November 7, 2025; 10:00 AM-12:00 PM CDT
Three Times Weekly In-Center Vadadustat vs. Standard Care Erythropoiesis-Stimulating Agent for CKD-Related Anemia in Patients Undergoing Dialysis (VOCAL)
Poster #: INFO10-FR
November 7, 2025; 10:00 AM-12:00 PM CDT
About Akebia Therapeutics
Founded in 2007, Akebia Therapeutics is intent on transforming the treatment landscape for those affected by kidney disease. With headquarters located in Cambridge, Massachusetts, the organization focuses on providing innovative, evidenced-based solutions. Interested individuals can find more about Akebia's mission by visiting their website.
About Vafseo (vadadustat) Tablets
As a once-daily oral treatment, Vafseo serves as a valuable option for managing anemia in CKD patients, activated through the body’s natural mechanisms to boost red blood cell production. It is notably available in over 37 countries.
Frequently Asked Questions
What is Akebia Therapeutics?
Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of those with kidney disease through innovative treatments and research.
What will Akebia present at ASN Kidney Week 2025?
Akebia will present key findings from clinical data on vadadustat, focusing on its benefits for CKD-related anemia.
Who is leading the oral presentation?
Dr. Glenn M. Chertow of Stanford University will present a crucial analysis on the impact of vadadustat.
What is Vafseo?
Vafseo (vadadustat) is a medication designed to manage anemia in CKD patients by enhancing the body’s natural production of red blood cells.
Where can I learn more about Akebia?
For more information, visit Akebia Therapeutics’ official website.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
